Enthusiastic doctors; starting science from 8 am !

Finerenone vs. Spironolactone
#HeartFailure2024

📌Timing of Cardio-Kidney Protection With #SGLT2 i : Insights From Four Large-Scale Placebo-Controlled Outcome Trials

#SGLT2 #CaReMe

HFrEFをMRAで治療中、eGFR 30 mL/min/1.73m2 切った時のMRAどうしてますか？

現場でよく遭遇する話ですが未だ答えがないところなので、RALES, EMPHASISの統合解析を行いました

結論、なるべく続けた方がよさそう

JACCからESCHFに合わせ同時掲載、読んでみて下さい

jacc.org/doi/10.1016/j.…

Combination therapy (RASi + SGLT2i+ MRA+ GLP1RA) can add another 5 years of dialysis free survival Brendon Neuen

#HeartFailure2024 #JACC SimPub: In pts w/ a 📉 in eGFR to <30 mL/min/1.73 m2, 21 fewer individuals (per 100 person-yrs) experienced primary outcome w/ MRA treatment, vs placebo, compared w/ an excess of 3 more pts w/ severe hyperkalemia (>6.0 mmol/L). bit.ly/4dz8Les

Mineralocorticoid Receptor Antagonists in #HF and Impaired Renal Function

👥4355 ➡️6.8% experienced a ↘️ of eGFR after randomization to <30 mL/min/1.73 m2

👉risk reduction in the primary outcome with MRA therapy was similar in those who experienced a decrease in eGFR to <30…

Amazing observation on #CKM overlapping with #HeartFailure from #RCTs #HeartFailure 2024 presented by Muthu Vaduganathan

Simpub late breaker #HFA2024 & JAMA
V142I TTR CV burden
HFH risk @ 63 (mostly HFrEF) and dth @ 72
Women/men similar
Carriers live 2-2.5 years less ➡️loss of ~1million years of life in US
🙏 scottdavidsolomon Svati Shah Robert Mentz, MD Sadiya Khan Parag Goyal MD MSc marianna fontana

⚠️ Timing of Cardio-Kidney Protection With SGLT2 Inhibitors: Insights From Four Large-Scale Placebo-Controlled Outcome Trials‼️

Soc Esp Cardiología SACardiología Asociación Cardiología Clínica SEC Cardiología Preventiva Síndrome CardioRenal y Congestión en IC Julio Marta Cobo Marcos S.E.N. Nefrología

ahajournals.org/doi/10.1161/CI…

Among self-reported Black individuals, male & female V142I transthyretin variant carriers faced similar & substantial risk for HF hospitalization, predominantly with reduced ejection fraction, & death, with steep age-dependent penetrance. ja.ma/4anxP5u #HeartFailure2024

CKM Syndrome: Prevalence & Staging

•CKM diseases (🫀, kidney, metabolic) affect > 25% of 🇺🇸adults
•~Leading cause of death in 2021➡️CKM syndrome staging in 2023
•Staging: 0 (no risk factors) to 4 (established cardiovascular disease), aiding in prevention & management

#HeartFailure2024 #JACCHF LBCT SimPub: First randomized, cross-over study examining the effectiveness of 3 diuretic regimens in the setting of an in-hospital HF day-care unit bit.ly/3wyAafV
🔹IV furosemide
🔹IV furosemide+oral metolazone
🔹IV furosemide+IV acetazolamide

Some powerful messages by Prof Javed Butler at the Eugene Braunwald Lecture: Some thoughts on clinical trial in #HF :

➡️on why we do #clinicaltrials : to reduce human suffering

➡️to the young folks: work hard, do what you love, and success will follow

#HeartFailure2024

#HeartFailure2024
HFA sim pub out now Journal of Cardiac Failure from Muthu Vaduganathan Carolyn Lam et al

Who’s ready for FineArts results?!

Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 Anu Lala-Trindade Andrew J Sauer MD Ryan J Tedford MD Nosheen Reza, MD Vanessa Blumer, MD, FACC Quentin Youmans, MD, MSc, FACC Shashank Sinha, MD, MSc, FACC, FAHA

Muthu Vaduganathan kickoff with the first presentation on the (surprisingly small😅) main stage of #HeartFailure2024 with a very clever study: Timing of Cardio-Kidney Protection With SGLT2 Inhibitors

SimPub in Circulation with Brendon Neuen

ahajournals.org/doi/abs/10.116…

🔥 #HeartFailure2024 #SimPub in Journal of Cardiac Failure

Generalizability of the Spectrum of Kidney Risk in the #FINEARTSHF Trial to US Adults with HF

bit.ly/3UTfys8

🔥Out now in #JCF ! This brief report shows that in the ongoing FINEARTS-HF trial, incorporating UACR reclassified kidney risk in 1/3 trial pts and US adults with HF, emphasizing the importance of albuminuria as part of comprehensive risk assessment.

🔗bit.ly/3UTfys8

#ARNI a proven therapy for patients with #HF ...

...but in broader populations, can #ARNI protect the heart after #COVID19 ?

🚨New #SimPub #HeartFailure2024 now in European Society of Cardiology Journals #EJHF

#PARACOR_19 pilot RCT

Duke Clinical Research Institute Michael Felker Javed Butler #LongCovid

onlinelibrary.wiley.com/doi/full/10.10…

Timing of Cardio-Kidney Protection With #SGLT2i : Insights From Four Large-Scale Placebo-Controlled Outcome Trials

Just Published in Circulation ahajournals.org/doi/10.1161/CI…

Brendon Neuen Muthu Vaduganathan
#HeartFailure2024 European Society of Cardiology European Society of Cardiology News